Valuation: TransMedics Group, Inc.

Market Cap 3.26B 2.96B 2.74B 2.47B 4.66B 305B 4.84B 32.96B 13.04B 164B 12.24B 11.98B 520B P/E 2026 *
62.2x
P/E 2027 * 39.4x
Enterprise Value 3.2B 2.9B 2.68B 2.42B 4.56B 299B 4.74B 32.3B 12.77B 161B 11.99B 11.74B 509B EV / Sales 2026 *
4.17x
EV / Sales 2027 * 3.42x
Free-Float
95.23%
Yield 2026 *
-
Yield 2027 * -
1 day+2.72%
1 week+4.65%
Current month+45.92%
1 month+34.48%
3 months+6.17%
6 months+40.90%
Current year-20.85%
1 week 89.5
Extreme 89.5
96.76
1 month 64.64
Extreme 64.64
97.56
Current year 60.1
Extreme 60.105
151.85
1 year 60.1
Extreme 60.105
156
3 years 55
Extreme 55
177.37
5 years 10
Extreme 10
177.37
10 years 10
Extreme 10
177.37
Manager TitleAgeSince
Chief Executive Officer 58 1998-07-31
Director of Finance/CFO 46 2026-09-20
Chief Operating Officer 43 2023-02-01
Director TitleAgeSince
Director/Board Member 58 1998-07-31
Chairman 81 2010-12-31
Director/Board Member 78 2016-01-31
Date Insider Type Main position Quantity % Market Cap. Importance
10/28/26 Free

Chief Financial Officer

57,388 0.1683%
9/11/26 Buy

Director

1,336 0.0039%
8/17/26 Don

Chairman

-18,000 0.0528%
Change 5-day change 1-year change 3-year change Capi.($)
+2.72%+4.65%-17.75%+37.87% 3.26B
-0.23%-4.18%+19.38%+46.62% 254B
+0.24%-3.17%+1.04%+7.97% 159B
-0.29%-3.53%-20.68%+39.29% 149B
+0.99%-3.51%-56.11%-20.04% 62.37B
+0.10%-0.01%+25.89%+57.46% 60.62B
+0.42%-0.16%+4.52%-13.10% 53.05B
+0.59%-1.60%+21.04%+52.75% 48.55B
-1.11%-6.26%+4.38%+59.87% 46.7B
+1.19%-2.86%+21.46%+75.31% 44.21B
Average +0.39%-2.29%+0.32%+34.40% 88B
Weighted average by Cap. -0.05%-2.99%+2.76%+33.29%

Financials

2026 *2027 *
Net sales 767M 696M 643M 580M 1.1B 71.67B 1.14B 7.75B 3.07B 38.68B 2.88B 2.82B 122B 901M 818M 756M 682M 1.29B 84.22B 1.34B 9.11B 3.6B 45.44B 3.38B 3.31B 144B
Net income 57.62M 52.31M 48.32M 43.59M 82.3M 5.38B 85.45M 582M 230M 2.91B 216M 212M 9.18B 98.37M 89.3M 82.49M 74.42M 140M 9.19B 146M 994M 393M 4.96B 369M 361M 15.67B
Net Debt -65.77M -59.71M -55.16M -49.76M -93.94M -6.15B -97.53M -665M -263M -3.32B -247M -242M -10.48B -176M -159M -147M -133M -251M -16.41B -260M -1.77B -702M -8.85B -659M -645M -27.97B
Projected Income Statement - Annual - TransMedics Group, Inc.
Logo TransMedics Group, Inc.
TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
Employees
898
Date Price Change Volume
26-11-18 US$96.51 +2.77% 55,369
26-11-17 US$93.91 +1.84% 960,724
26-11-16 US$92.21 +0.91% 564,384
26-11-13 US$91.38 -0.67% 840,859
26-11-12 US$92.00 -0.01% 1,054,603
Trader
Investor
Global
Quality
ESG MSCI
BB
MarketScreener Ratings - TransMedics Group, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
93.91USD
Average target price
104.55USD
Spread / Average Target
+11.33%
  1. Stock Market
  2. Stocks
  3. TMDX Stock